160 related articles for article (PubMed ID: 34297961)
1. Introducing rotavirus vaccine in eight sub-Saharan African countries: a cost-benefit analysis.
Okafor CE; Ekwunife OI
Lancet Glob Health; 2021 Aug; 9(8):e1088-e1100. PubMed ID: 34297961
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study.
Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Atherly D
Lancet Glob Health; 2021 Jul; 9(7):e942-e956. PubMed ID: 33891885
[TBL] [Abstract][Full Text] [Related]
3. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study.
Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Kallen L; Atherly D
Lancet Glob Health; 2019 Dec; 7(12):e1664-e1674. PubMed ID: 31708147
[TBL] [Abstract][Full Text] [Related]
4. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines.
Pecenka C; Debellut F; Bar-Zeev N; Anwari P; Nonvignon J; Shamsuzzaman M; Clark A
Vaccine; 2018 Nov; 36(49):7472-7478. PubMed ID: 30420039
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of rotavirus vaccination in Mozambique.
Lourenço Guimarães E; Chissaque A; Pecenka C; Clark A; Vaz B; Banze A; Canana N; Romão C; do Rosário Oliveira Martins M; de Deus N; Debellut F
Vaccine; 2022 Aug; 40(36):5338-5346. PubMed ID: 35933279
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study.
Villanueva-Uy MET; Lam HY; Aldaba JG; Uy TMZ; Valverde HA; Silva MWT; Mooney J; Clark A; Pecenka C
Vaccine; 2021 Nov; 39(48):7091-7100. PubMed ID: 34753614
[TBL] [Abstract][Full Text] [Related]
7. Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia.
Lusvan ME; Debellut F; Clark A; Demberelsuren S; Otgonbayar D; Batjargal T; Purevsuren S; Groman D; Tate J; Pecenka C
Vaccine; 2019 Feb; 37(6):798-807. PubMed ID: 30639458
[TBL] [Abstract][Full Text] [Related]
8. Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC.
Debellut F; Jaber S; Bouzya Y; Sabbah J; Barham M; Abu-Awwad F; Hjaija D; Ramlawi A; Pecenka C; Clark A; Mvundura M
PLoS One; 2020; 15(2):e0228506. PubMed ID: 32023295
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data.
Bar-Zeev N; Tate JE; Pecenka C; Chikafa J; Mvula H; Wachepa R; Mwansambo C; Mhango T; Chirwa G; Crampin AC; Parashar UD; Costello A; Heyderman RS; French N; Atherly D; Cunliffe NA;
Clin Infect Dis; 2016 May; 62 Suppl 2(Suppl 2):S220-8. PubMed ID: 27059360
[TBL] [Abstract][Full Text] [Related]
10. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
Bergman H; Henschke N; Hungerford D; Pitan F; Ndwandwe D; Cunliffe N; Soares-Weiser K
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD008521. PubMed ID: 34788488
[TBL] [Abstract][Full Text] [Related]
11. Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications.
Okafor CE
Pharmacoecon Open; 2021 Sep; 5(3):545-557. PubMed ID: 33410094
[TBL] [Abstract][Full Text] [Related]
12. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
16. Impact of rotavirus vaccines in Sub-Saharan African countries.
Mwenda JM; Parashar UD; Cohen AL; Tate JE
Vaccine; 2018 Nov; 36(47):7119-7123. PubMed ID: 29914848
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi.
Niyibitegeka F; Riewpaiboon A; Youngkong S; Thavorncharoensap M
Vaccine; 2021 Feb; 39(8):1272-1282. PubMed ID: 33487467
[TBL] [Abstract][Full Text] [Related]
19. Health and economic impact of rotavirus vaccination in GAVI-eligible countries.
Kim SY; Sweet S; Slichter D; Goldie SJ
BMC Public Health; 2010 May; 10():253. PubMed ID: 20470426
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of rotavirus vaccination in Malawi.
Berry SA; Johns B; Shih C; Berry AA; Walker DG
J Infect Dis; 2010 Sep; 202 Suppl(Suppl 1):S108-15. PubMed ID: 20684689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
